Ewing's sarcoma is a malignant bone-associated tumor of children and young adults. Most cases of Ewing's sarcoma express the EWS/FLI fusion protein. EWS/FLI functions as an aberrant ETS-type transcription factor and serves as the master regulator of Ewing's sarcoma-transformed phenotype. We recently showed that EWS/FLI regulates one of its key targets, NR0B1, through a GGAAmicrosatellite in its promoter. Whether other critical EWS/FLI targets are also regulated by GGAA-microsatellites was unknown. In this study, we combined transcriptional analysis, whole genome localization data, and RNA interference knockdown to identify glutathione S-transferase M4 (GSTM4) as a critical EWS/FLI target gene in Ewing's sarcoma. We found that EWS/FLI directly binds the GSTM4 promoter, and regulates GSTM4 expression through a GGAA-microsatellite in its promoter. Reduction of GSTM4 levels caused a loss of oncogenic transformation. Furthermore, reduction of GSTM4 resulted in an increased sensitivity of Ewing's sarcoma cells to chemotherapeutic agents, suggesting a role for this protein in drug resistance. Consistent with this hypothesis, patients with Ewing's sarcoma whose tumors had higher levels of GSTM4 expression had worse outcomes than those with lower expression levels. These data show that GSTM4 contributes to the cancerous behavior of Ewing's sarcoma and define a wider role for GGAA-microsatellites in EWS/FLI function than previously appreciated. These data also suggest a novel therapeutic resistance mechanism, in which the central oncogenic abnormality directly regulates a resistance gene.
formation
Most cases of Ewing's sarcoma harbor recurrent chromosomal translocations, the most common of which encodes the EWS/FLI fusion oncoprotein (Delattre et al., 1992) . EWS/FLI requires both its strong transcriptional activation domain (derived from EWS) and its ETS-type DNA-binding domain (derived from FLI) for oncogenic function (May et al., 1993a, b) . A variety of studies have identified a large number of EWS/FLI-regulated genes (Prieur et al., 2004; Smith et al., 2006) . However, only a handful of these genes have been shown to participate in Ewing's sarcoma oncogenesis. It seems likely that other EWS/FLIregulated genes will be involved in oncogenic transformation or other cancer-relevant phenotypes, such as invasion, migration, angiogenesis or drug resistance. One of the challenges, however, for identifying which EWS/FLI targets participate in cancer-relevant phenotypes is the complexity of assays required to assess many of these phenotypes, which precludes the development of high-throughput screening approaches. An alternate approach, then, is to limit the number of gene products to be assessed in a lower-throughput screening assays, for example, by comparing microarray profiles across multiple different experiments (Kinsey et al., 2006; Hancock and Lessnick, 2008) , or by identifying which genes are 'direct' EWS/FLI targets .
We recently showed that EWS/FLI uses a GGAAmicrosatellite to regulate NR0B1, a gene that is required for oncogenic transformation in Ewing's sarcoma cells (Kinsey et al., 2006; . During the course of these studies, we identified thousands of GGAA-microsatellite-containing genes, suggesting that at least a portion of these might be regulated by direct binding of EWS/FLI to their promoters. We further hypothesized that other GGAA-microsatellite-containing genes might also be required for oncogenic transformation, or other cancer-relevant phenotypes (Gangwal and Lessnick, 2008) .
To evaluate this hypothesis, we now compare three data sets we had previously generated to identify genes that might be directly regulated by EWS/FLI though GGAA-microsatellites. These data sets included (i) the transcriptional profile of EWS/FLI in Ewing's sarcoma cells (produced by comparing patient-derived Ewing's sarcoma cells with retroviral-mediated RNA interference (RNAi) constructs targeting EWS/FLI with those harboring control constructs; Kinsey et al., 2006; Smith et al., 2006) , (ii) genome-wide localization data of EWS/ FLI in Ewing's sarcoma cells (produced by 'ChIP-chip' experiments; and (iii) comprehensive mapping data of GGAA-microsatellites in the human genome (produced computationally; . Through these cross-platform comparisons, we identified genes that have all of the characteristics we sought. These genes include previously identified EWS/ FLI targets such as NR0B1, FCGRT and CAV1 (Tirado et al., 2006; . In addition, we identified glutathione S-transferase mu 4 (GSTM4) as a potential new EWS/FLI target gene in Ewing's sarcoma.
Glutathione S-transferases (GST) are detoxification enzymes which inactivate a variety of endogenous and exogenous reactive compounds by conjugation to glutathione. At present, eight distinct classes (alpha, kappa, mu, omega, sigma, theta, pi and zeta) of soluble and six membrane-bound GSTs have been identified. GSTM4 belongs to the mu class of soluble forms.
GSTM4 has a high level of amino-acid sequence identity, but distinct physiochemical properties and tissue distributions, as compared with other GSTMs (Comstock et al., 1993 (Comstock et al., , 1994 . GSTM4 does not show comparable activity with the standard GST substrate and its specific substrates have yet to be identified. GST genes are known to be highly polymorphic to accommodate an increasing number of foreign compounds (Hayes and Strange, 2000) . This polymorphism can change an individual's susceptibility to disease and responsiveness to therapeutic drugs. For instance, a T2517C polymorphism in GSTM4 was shown to associate with an increased risk of developing lung cancer (Liloglou et al., 2002) . The mechanistic basis for this association is currently unknown.
To evaluate the role of EWS/FLI in regulating GSTM4, we first extracted the GSTM4 data from our transcriptional profiling studies (Kinsey et al., 2006; Smith et al., 2006) . In these studies, two different retroviral RNAi constructs targeting the 3 0 -UTR of endogenous EWS/FLI (EF-2-RNAi and EF-4-RNAi) were introduced into patient-derived Ewing's sarcoma Luciferase assays using a pGL3-promoter luciferase vector (Promega Corporation, Madison, WI, USA) containing the GSTM4 GGAA-microsatellite, or an empty control vector, co-transfected into TC71 Ewing's sarcoma cells with the EWS/FLI RNAi construct (EF-2-RNAi), or a negative control construct (ERG-RNAi). Luciferase activities were determined as previously described . (e) Luciferase assays using a pGL3-promoter luciferase vector containing the GSTM4 GGAA-microsatellite, or an empty control vector, co-transfected into HEK293 cells with an EWS/FLI cDNA expression vector, or an empty negative control construct . (f) Chromatin immunoprecipitation of the GGAA-microsatellite-containing region of the GSTM4 promoter from A673 cells was carried out by using antibodies against FLI (which recognizes EWS/FLI), ETS1 or ELK1 (see for experimental details; primer sequences available upon request). Data are plotted as the fold enrichment with respect to the average enrichment of two negative controls. The error bars indicate the s.e. of the mean of two to five independent experiments. GSTM4 in Ewing's sarcoma W Luo et al cell lines A673, TC71 and EWS502, and were compared with a similar RNAi construct targeting the luciferase gene (luc-RNAi) as a negative control (which is not present in the cells used). We found that knock down of EWS/FLI resulted in the reduced levels of GSTM4 mRNA levels in Ewing's sarcoma cell lines (Figure 1a , data not shown). This result was confirmed using quantitative reverse transcription-PCR, in which knock down of EWS/FLI resulted in an approximately 80% decrease in GSTM4 expression (Figure 1b) . Unfortunately, we were unable to assess protein levels as the currently available antibodies were inadequate for western blot experiments.
Direct inspection of the GSTM4 promoter revealed the presence of a GGAA-microsatellite, consisting of 18 GGAA repeats (Figure 1c) . We have previously shown that a GGAA-microsatellite regulates the NR0B1 gene in Ewing's sarcoma cells, and that EWS/FLI is capable GSTM4 in Ewing's sarcoma W Luo et al of binding GGAA-microsatellites in vitro as well as in vivo (Gangwal and Lessnick, 2008; . To determine whether the GGAA-microsatellite in the GSTM4 promoter is an EWS/FLI-response element, we cloned this element upstream of a minimal promoter and a luciferase reporter cDNA. This construct was EWS/FLI responsive in TC71 Ewing's sarcoma cells, as shown by relatively high levels of luciferase activity when co-transfected with an ERGRNAi negative control vector, and an B85% reduction in luciferase reporter activity when EWS/FLI was knocked down with an EWS/FLI RNAi construct (EF-2-RNAi; Figure 1d ). In complementary experiments, we found that co-transfection of the luciferase reporter with an EWS/FLI cDNA in HEK293 cells resulted in an ninefold stimulation as compared with cotransfections with an empty vector negative control construct ( Figure 1e ). To determine whether EWS/FLI occupied the GSTM4 promoter in vivo, we carried out directed chromatin immunoprecipitation experiments (ChIP) using antibodies and conditions we previously validated . We found that immunoprecipitation of EWS/FLI pulled down the GSTM4 microsatellite region, whereas immunoprecipitation of two other ETS family members, ETS1 and ELK1, did not (Figure 1f ). Taken together, these data support our hypothesis that GSTM4 is upregulated in Ewing's sarcoma cells by direct binding of EWS/FLI to the GGAA-microsatellite in the GSTM4 promoter.
We next sought to determine whether GSTM4 has a functional role in Ewing's sarcoma. First, we investigated whether GSTM4 is required for maintaining oncogenic phenotype of Ewing's sarcoma through a loss-of-function approach. We designed small hairpin RNAs against the 3 0 -UTR of GSTM4 and cloned these into retroviral constructs (called GSTM4-4-RNAi and GSTM4-5-RNAi). Polyclonal-infected and -selected populations of A673 Ewing's sarcoma cells showed an efficient reduction of endogenous GSTM4 mRNA levels as assessed by quantitative reverse transcription-PCR, as compared with cells infected with the negative control luc-RNAi retrovirus (Figure 2a) . We found that cells in which GSTM4 was knocked down grew slightly more slowly than control cells in tissue culture (Figure 2b) . Importantly, decreased GSTM4 expression resulted in a significant reduction in oncogenic transformation, as shown by diminished anchorage-independent growth in soft agar experiments (Figure 2c ). The fact that two different retroviral RNAi constructs showed nearly identical phenotypes in two different patient-derived Ewing's sarcoma cell lines suggested that these results are specific to reduced GSTM4 expression, and were not 'off-target' effects. These results show that ongoing GSTM4 expression is required for the transformed phenotype of Ewing's sarcoma. To determine whether GSTM4 is required for oncogenic transformation in other tumor types, we depleted GSTM4 from U2OS osteosarcoma cells and found that neither cell growth nor colony formation in soft agar was changed (data not shown). Furthermore, knockdown of GSTM4 in RH28 rhabdomyosarcoma cells did not alter cell growth in tissue culture, but as these cells did not form colonies in soft agar at baseline, the effects of GSTM4 loss on oncogenic transformation could not be assessed (data not shown). These data indicate that a role for GSTM4 in proliferation and oncogenic transformation is likely specific to Ewing's sarcoma.
Therapeutic approaches to Ewing's sarcoma consist of either surgery and/or radiation therapy to the primary site of disease, along with intensive systemic chemotherapy to eradicate micrometastatic disease. We reasoned that because GST enzymes detoxify various reactive compounds, including therapeutic drugs, GSTM4 might contribute to the resistance profile of Ewing's sarcoma to chemotherapeutic agents. To test this possibility, we prepared Ewing's sarcoma cells with either wild-type (luc-RNAi) or reduced levels (GSTM4-4-RNAi) of GSTM4, and treated them with increasing dosages of chemotherapeutic drugs that are currently used to treat patients with Ewing's sarcoma, including etoposide, doxorubicin and melphalan, and tested cell survival using an MTT assay. We found that knockdown of GSTM4 resulted in an increase in sensitivity to etoposide as compared with luc-RNAi-infected cells in three different patient-derived Ewing's sarcoma cell lines (A673, TC71 and EWS502; Figure 3a -c). This effect was specific for etoposide among the initial agents tested, as there were no differences in sensitivity to doxorubicin or melphalan following GSTM4 knockdown (Figure 3d , data not shown).
The synthetic retinoid derivative fenretinide (4-hydroxy(phenyl) retinamide) has been reported to induce high levels of cell death in Ewing's sarcoma cell lines in vitro and to delay growth of Ewing's sarcoma xenografts in vivo (Magwere et al., 2008; Myatt and Burchill, 2008) . Interestingly, it was recently reported that depletion of glutathione by pretreatment with l-buthionine (S,R) sulphoximine-sensitized Ewing's sarcoma cells to the toxic effects of fenretinide (Magwere et al., 2008) . This suggested that fenretinide toxicity is modulated by glutathione-dependent functions in Ewing's sarcoma cells. On the basis of these observations, we next investigated whether the function of a glutathionedependent enzyme (GSTM4) would alter the sensitivity of Ewing's sarcoma cells for fenretinide. We found that Ewing's sarcoma cells with reduced GSTM4 levels (through the GSTM4-4-RNAi construct) were more sensitive to fenretinide than cells containing a control RNAi construct (luc-RNAi; Figures 3e and f) . Because fenretinide is known to generate reactive oxygen species in Ewing's sarcoma cells (Magwere et al, 2008) , we tested whether GSTM4 depletion in A673 cells caused alterations in reactive oxygen species production using a cell permeable dye (5-(6)-chloromethyl-2 0 ,7 0 -dichlorodihydrofluorescein diacetate acetyl ester).
We found that there were no significant changes in reactive oxygen species production following reduction of GSTM4 levels with the GSTM4-4-RNAi construct (data not shown). Taken together, the drug-sensitivity data show that the reduction of GSTM4 levels confer increased sensitivity to some cytotoxic agents in Ewing's sarcoma, and further suggest that inhibition of GSTM4 activity might be used in combination with chemotherapy to increase therapeutic responses in Ewing's sarcoma.
Because GSTM4 modulates Ewing's sarcoma oncogenic transformation and therapeutic resistance, we Ewing's Sarcoma-Primary Tumors Figure 4 GSTM4 expression in tumors correlates with overall survival in Ewing's sarcoma patients. Analysis was performed following the Institutional Review Board approval. Forty four cases of morphologically confirmed Ewing's sarcoma pretreatment primary tumor samples (from the University of Michigan Medical Center Department of Pathology) included on a tissue microarray (TMA) were analysed by double immunofluorescence staining for both CD99 (which marks Ewing's sarcoma tumor cells; Abcam, Cambridge, MA, USA, Ab-27271, rabbit polyclonal antibody, 1:100) and GSTM4 (Abcam, ab-49484, mouse monoclonal antibody, 1:80). The AQUA system was used for the automated image acquisition and analysis. Briefly, images of each TMA core were captured with an Olympus BX51 microscope at different extinction/emission wavelengths. Within each TMA spot, the area of tumor was distinguished from stromal and necrotic areas by creating a tumor-specific mask from the CD99-staining pattern, which was visualized using the Alexa Fluor 555 signal. Within the masked region, the fluorescence pixel intensity of the GSTM4 protein/antibody complex was obtained from the Cy5 signal and reported as pixel intensity from 0 to 3000. In cases where multiple primary pretreatment tumor samples were present, the average of the values from each sample was used. Patients were stratified into two groups, those with relatively low-level GSTM4 expression (0-1000; n ¼ 10), and those with relatively high-level GSTM4 expression (1000-3000; n ¼ 34). These data were plotted with stratified Kaplan-Meier curves using the outcome data from the University of Michigan. Cox proportional hazards models were fit using the counting process formulation of Andersen and Gill, 1982 . Goodness of fit was tested using the method presented in Grambsch and Therneau, 1994 . All statistical analysis was performed using R 2.8.0 statistical software (Copyright 2008, The R Foundation for Statistical Computing, Vienna, Austria). The 'survival' package in R was used for the survival analysis.
hypothesized that patients whose tumors exhibited higher levels of GSTM4 expression would have a worse outcome than patients whose tumors expressed lower levels of the protein. To test this hypothesis, we stained tissue microarrays containing Ewing's sarcoma tumor specimens for GSTM4 protein, using immunohistochemistry, and read out the results in a semiquantitative manner using an AQUA system (HistoRx, New Haven, CT, USA) (Camp et al., 2008) . As anticipated by our hypothesis, we found that patients with higher GSTM4 levels in their primary tumors had lower overall survival rates, although this result did not reach statistical significance due to a small sample size (P ¼ 0.054 by likelihood ratio test; Figure 4 ). These data support the notion that higher GSTM4 levels are correlated with therapeutic resistance and worse outcome in Ewing's sarcoma.
The data in this report show that GSTM4 is a direct target gene of the EWS/FLI oncoprotein and is required for oncogenic transformation and therapeutic drug resistance in Ewing's sarcoma cells. These findings show the utility of combining transcriptional profiling, ChIP-chip and computational promoter analyses in the identification of target genes that are involved in oncogenesis and other cancer-relevant phenotypes, such as drug resistance. Indeed, our observation that GSTM4 has a role in resistance to therapeutic agents in this disease suggests a new paradigm for drug resistance: that key oncogenic events involved in tumorigenesis may directly regulate drug resistance programs, in addition to their more widely recognized role in promoting oncogenic transformation. This has important implications for the design of molecularly targeted agents. We would predict that agents targeting EWS/FLI (such as cytarabine or RNAi-based approaches; Dubois et al., 2008; Hu-Lieskovan et al., 2005; Kinsey et al., 2006; Owen et al., 2008; Stegmaier et al., 2007) might be most effective when combined with standard cytotoxic agents. In this way, the loss of the key oncoprotein will reduce both oncogenic transformation and drug resistance, thereby allowing the tumor to be more effectively treated with standard chemotherapies. Conversely, inhibitors of GSTM4, if developed, may also be combined with standard chemotherapeutics to provide more efficacy in tumor kill by these agents.
